Upload
umesh-prajapati
View
74
Download
0
Embed Size (px)
Citation preview
Chapter-8 References
NIMS Institute of Pharmacy, NIMS University Jaipur Page 80
REFERENCES:-
1. Chien YW, 1992,. “Novel drug delivery systems”, 2nd Edition; Marcel
Dekker Inc: New York, 139-40.
2. Wani M., 2008, “Controlled Released System - A Review”,
Pharmainfo.net , Vol. 6, Issue 1,.
3. Hui HW, Robinson JR, Lee VHL. “Design and fabrication of oral
controlled release drug delivery systems”. In: Robinson JR, Lee V, editors.
Controlled drug delivery fundamentals and applications. 2nd
Ed.; Marcel
Dekker: New York: Inc; p. 373-4.
4. Jantzen GM, Robinson JR, 1996, “Sustained- and controlled-release drug
delivery systems.” In: Banker GS, Rhodes CT, editors. Modern
pharmaceutics. 3rd
Ed.; Marcel Dekker Inc; New York; 575-609.
Gudsoorkar VR, Rambhau D., 1993, “Extended release of drugs”. The
Eastern Pharmacist, 36(429); 17-22.
5. Lachman L, Lieberman HA, Kanig JL., 1987, “The theory and practice of
industrial pharmacy”, 3rd
Ed.; Varghese Publishing House Bombay, 293-
345,430.
6. Remington: The science and Practice of Pharmacy., 19th
Ed.; 1660, 1676,
1995.
7. Robinson J. R. Lee L. H., 1987, “Controlled Drug Delivery: Fundamentals
and Applications”, 2nd
Ed. 29, 312-319.
8. Alderman D. A., 1984, “International Journal of Pharmaceutical
Technology and Product Manufacture”. , 1(5).
9. M Flu Lu et al, 1991, “Drug Dev. Ind. Pharm”, 17(4), 1987-2004,.
10. Nigayale A. G. et al. , 1990, “Drug Dev. Ind. Pharm” 16, 2-8.
11. Pandey V., Manavalan R., Rajan T. et al, 2003, “Formulation and release
characteristics of Extended release diltiazem hydrochloride tablet”, Indian
Journal of Pharmaceutical Science , 65(1):44-8.
12. Hoffman A., 1998, “Pharmacodynamic aspects of Extended release
preparations”, Adv Drug Del Rev, 33: 185-99.
13. Jain NK, 2002, “Controlled and novel drug delivery”, 1st Ed.; CBS
Publishers; New Delhi
Chapter-8 References
NIMS Institute of Pharmacy, NIMS University Jaipur Page 81
14. Yie W, Chien, 2005, “Rate controlled drug delivery systems.” 2nd
Ed.
Marcel Dekker; New York, Revised and expanded,.
15. Jose G., Hossein O, Khalid S, 2003, “Progress in gastroretentive drug
delivery systems. Solid dose research and development”, Pharmatech, 152-
56.
16. Jaber E, Naser D, 2004, “Formulation of sustrained release lithium
carbonate matrix tablets: influence of hydrophilic materials on the release
rate and in vitro – in vivo evaluation”, Journal Pharmaceutical Science, 7:
338-44.
17. Aditya ST, Ketan AM, Larry LA, Stephen WH, 2004, “Influence of
methacrylic and acrylic acid polymers on the release performance of
weakly basic drugs from Extended release hydrophilic matrix”, Journal
Pharmaceutical Science.,93,2319-31.
18. Chowhan ZT. Role of binders in moisture-induced hardness increase in
compressed tablets and its effect on in vitro disintegration and dissolution.
J Pharm Sci 1980; 69: 1–4.
19. Rowe RC. The adhesion of film coatings to tablet surfaces – the effect of
some direct compression excipients and lubricants. J Pharm Pharmacol
1977; 29: 723–726.
20. Rowe RC. The molecular weight and molecular weight distribution of
hydroxypropyl methylcellulose used in the film coating of tablets. J Pharm
Pharmacol 1980; 32: 116–119.
21. Banker G, Peck G, Jan S, Pirakitikulr P. Evaluation of hydroxypropyl
cellulose and hydroxypropyl methyl cellulose as aqueous based film
coatings. Drug Dev Ind Pharm 1981; 7: 693–716.
22. Okhamafe AO, York P. Moisture permeation mechanism of some aqueous-
based film coats. J Pharm Pharmacol 1982; 34 (Suppl.): 53P.
23. Alderman DA, Schulz GJ. Method of making a granular, cold water
dispersible coating composition for tablets. United States Patent No.
4,816,298; 1989.
24. Patell MK. Taste masking pharmaceutical agents. United States Patent No.
4,916,161; 1990.
Chapter-8 References
NIMS Institute of Pharmacy, NIMS University Jaipur Page 82
25. Hardy JG, Kennerley JW, Taylor MJ, et al. Release rates from sustained-
release buccal tablets in man. J Pharm Pharmacol 1982; 34 (Suppl.): 91P.
26. Hogan JE. Hydroxypropylmethylcellulose sustained release technology.
Drug Dev Ind Pharm 1989; 15: 975–999.
27. Shah AC, Britten NJ, Olanoff LS, Badalamenti JN. Gel-matrix systems
exhibiting bimodal controlled release for oral delivery. J Control Release
1989; 9: 169–175.
28. Wilson HC, Cuff GW. Sustained release of isomazole from matrix tablets
administered to dogs. J Pharm Sci 1989; 78: 582–584.
29. Dahl TC, Calderwood T, Bormeth A, et al. Influence of physicochemical
properties of hydroxypropyl methylcellulose on naproxen release from
sustained release matrix tablets. J Control Release 1990; 14: 1–10.
30. Banker G, Peck G, Williams E, et al. Microbiological considerations of
polymer solutions used in aqueous film coating. Drug Dev Ind Pharm
1982; 8: 41–51.
31. Anonymous. Final report on the safety assessment of
hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose,
hydroxypropyl methylcellulose and cellulose gum. J Am Coll Toxicol
1986; 5(3): 1–60.
32. FAO/WHO. Evaluation of certain food additives and contaminants. Thirty-
fifth report of the joint FAO/WHO expert committee on food additives.
World Health Organ Tech Rep Ser 1990; No. 789.
33. Lewis RJ, ed. Sax’s Dangerous Properties of Industrial Materials, 11th
edn. New York: Wiley, 2004: 2054.
34. UCB (2007-11-29). "UCB Announces FDA Filing for drug-x in the
Treatment of Diabetic Neuropathic Pain". Press release. Retrieved 2007-
11-29
35. National Society for Epilepsy. Epilepsy: Information on epileptic
seizures.Available
at:http://www.epilepsynse.org.uk/PAGES/whatsnew/pr/ep_facts.cfm
[Accessed 15 August 2008].
Chapter-8 References
NIMS Institute of Pharmacy, NIMS University Jaipur Page 83
36. Ben-Menachem, E. Lacosamide: an investigational drug for adjunctive
treatment of partial-onset seizures. Drugs of Today 2007; 43 Available at:
www.prous.com/journals
37. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000506/
38. Gupta s., Kapoor V., Kapoor B., Itopride: A Novel Prokinetic agent; JK
Science A Drug Review; 2004; 6(2); 106-108.
39. Mcquaid KR., Dyspepsia. In: Mark Feldman et al (eds.), Sleisenger &
Fordtran's Gastrointestinal and Liver Disease
Pathophysiology/Diagnosis/Management.7th edition 2002; 1; 102-18.
40. Pasricha PJ., Prokinetic agents, antiemetics agents used in irritable bowel
syndrome. In: Hardman JG et al (eds.), Goodman and Gilman'ss The
Pharmacological Basis of Therapeutics, 10th edition, New York, McGraw
Hill Book Inc.; 2001; 1021.
41. Wysowski DK., Corken A., Gallo TH et al. Post-marketing reports of QT
prolongation & ventricular arrhythmias in association with cisapride and
food and Drug administration regulatory actions; American Journal of
Gastroenterology; 2001; 96; 1698-1703.
42. Mushiroda T., Douya R., Takahara E., Nagata O., The involvement of
flavin containing monooxygenase but not CYP3A4 in metabolism
of itopride hydrochloride, a gastrokinetic agent: comparison with cisapride
and Mosapride citrate. Drug Metab Dispos 2000; 28: 1231-37.
43. Gupta s., Kapoor V., Kapoor B., Itopride: A Novel Prokinetic agent; JK
Science A Drug Review; 2004; 6(2); 106-108.
44. Mcquaid KR., Dyspepsia. In: Mark Feldman et al (eds.), Sleisenger &
Fordtran's Gastrointestinal and Liver Disease
Pathophysiology/Diagnosis/Management.7th edition 2002; 1; 102-18.
45. Pasricha PJ., Prokinetic agents, antiemetics agents used in irritable bowel
syndrome. In: Hardman JG et al (eds.), Goodman and Gilman'ss The
Pharmacological Basis of Therapeutics, 10th edition, New York, McGraw
Hill Book Inc.; 2001; 1021.
46. Wysowski DK., Corken A., Gallo TH et al. Post-marketing reports of QT
prolongation & ventricular arrhythmias in association with cisapride and
Chapter-8 References
NIMS Institute of Pharmacy, NIMS University Jaipur Page 84
food and Drug administration regulatory actions; American Journal of
Gastroenterology; 2001; 96; 1698-1703.
47. Mushiroda T., Douya R., Takahara E., Nagata O., The involvement of
flavin containing monooxygenase but not CYP3A4 in metabolism
of itopride hydrochloride, a gastrokinetic agent: comparison with cisapride
and Mosapride citrate. Drug Metab Dispos 2000; 28: 1231-37.
48. http://www.symedlabs.com/p6.htm
49. Kibbe AH., Handbook of pharmaceutical excipients; American
Pharmaceutical Association and Pharmaceutical Press, Washington
London; 2000; 3rd Ed; 102-106.
50. Lachman L., Lieberman HA., Kanig JL., The theory and practice of
Industrial pharmacy, Varghese Publishing House Bombay; 1987; 171-293.
51. Aulton ME., The Science of dosage form design; Churchill living stone;
2002; 2nd edition; 414-418.
52. Cooper J, Gun C, Powder Flow and Compaction. Inc Carter SJ, Eds.
Tutorial Pharmacy. New Delhi, hidix CBS Publishers and Distributors;
1986:211-233.
53. Martin A, Micromeretics, In: Martin A, ed. Physical Pharmacy.Baltimores,
MD: Lippincott Williams and Wilkins; 2001:423-454.
54. ICH topic 8 Pharmaceutical guidelines, Note for Guidance on
Pharmaceutical Developments, (EMEA/CHMP167068/2004).
55. Baertschi, S. W., Pharmaceutical stress testing, predicting drug
degradation, Taylor and Francis group, 2005, 344-350.
56. The Indian Pharmacopoeia; Ministry of Health and Family Welfare,
Government of India, Controller of Publications, New Delhi; 1996; 4th
Edition; Volume II.
57. Moore JW., Flanner HH., Mathematical comparison of curves with an
emphasis on in-vitro dissolution profiles; Pharmaceutical Technology;
1996; 20(6); 64-74.
58. Paulo C., Jose Manuel, Sousa L., Modeling and comparison of dissolution
profiles; European Journal of Pharmaceutical Science; 2001; 13; 123-133.
Chapter-8 References
NIMS Institute of Pharmacy, NIMS University Jaipur Page 85
59. Korsmeyer RW., Peppas NA., Effect of the morphology of hydrophilic
polymeric matrices on the diffusion and release of water soluble drugs,
Journal of Membr. Science; 1981; 9; 211–227.
60. Higuchi T., Mechanism of sustained action medication, Theoretical
analysis of rate release of solid drugs dispersed in solid matrices; Journal
of Pharmaceutical Science; 1963; 52; 1145-1149.
61. ICH GUIDELINES Q1A (R2), Guidance for industry, stability testing of
new drug substance and products (Available on: http://
http://www.ich.org).